Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

Alnylam Pharmaceuticals wanted to move beyond fragmented analytics, siloed dashboards and slow, static reporting cycles common across healthcare and life sciences. Komodo expanded its partnership with Alnylam, extending its Marmot analytics AI platform from an initial August 2025 commercial-operations launch to customer-facing and enterprise-wide use, with Alnylam integrating diverse enterprise datasets and deploying custom AI agents across critical workflows. The result: reporting cycles dropped from months to hours, teams gained access to previously unreachable insights, and the company eliminated reliance on fragmented dashboards in favor of a unified, data-driven decision-making foundation.

Komodo Health runs the 'Healthcare Map,' one of the largest linked longitudinal patient-record graphs sold commercially into pharma for real-world analytics.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.